Jefferies Group Gives Buy (N/A) Rating to ViroPharma Incorporated (VPHM)
VPHM has been the subject of a number of other recent research reports. Analysts at Oppenheimer (NYSE: OPY) downgraded shares of ViroPharma Incorporated from an “outperform” rating to a “market perform” rating in a research note to investors on Tuesday, May 1st. Separately, analysts at Goldman Sachs (NYSE: GS) cut their price target on shares of ViroPharma Incorporated from $26.00 to $22.00 in a research note to investors on Wednesday, April 11st. They now have a “neutral” rating on the stock. Finally, analysts at Auriga reiterated a “hold” rating on shares of ViroPharma Incorporated in a research note to investors on Wednesday, April 11st.
ViroPharma Incorporated opened at 19.83 on Tuesday. ViroPharma Incorporated has a 52-week low of $14.62 and a 52-week high of $33.17. The company has a market cap of $1.383 billion and a price-to-earnings ratio of 12.83.
ViroPharma Incorporated last posted its quarterly earnings results on Tuesday, May 1st. The company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by $0.05. The company’s quarterly revenue was up 7.1% on a year-over-year basis. On average, analysts predict that ViroPharma Incorporated will post $0.08 earnings per share next quarter.
ViroPharma Incorporated (ViroPharma) is a global biotechnology company focused on the development and commercialization of products that address diseases, with a focus on products used by physician specialists or in hospital settings.